APO Research
Talk to an analyst

APO RESEARCH · REPORT

Anthrax Vaccines

Anthrax is a serious disease that can affect both animals and humans. It is caused by bacteria called Bacillus anthracis. People can get anthrax from contact with infected animals, wool, meat, or hides.Anthrax vaccine protects against anthrax disease. Anthrax vaccine was licensed in 1970.Based on limited but sound evidence, the vaccine protects against both cutaneous (skin) and inhalation anthrax.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Anthrax is a serious disease that can affect both animals and humans. It is caused by bacteria called Bacillus anthracis. People can get anthrax from contact with infected animals, wool, meat, or hides.Anthrax vaccine protects against anthrax disease. Anthrax vaccine was licensed in 1970.Based on limited but sound evidence, the vaccine protects against both cutaneous (skin) and inhalation anthrax.

Selected research

Market Outlook & Growth Opportunities

Global Anthrax Vaccines Market Outlook and Growth Opportunities 2026

1 January 2026219 pages

Choose your research edition.

Industry ResearchAnthrax Vaccines Industry Research Report 2026146 pages · $2,950 USDIndustry Growth & TrendsGlobal Anthrax Vaccines Industry Growth and Trends Forecast to 2032120 pages · $3,450 USDMarket StructureGlobal Anthrax Vaccines Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Anthrax Vaccines Market Outlook and Growth Opportunities 2026219 pages · $4,250 USDMarket Analysis & ForecastGlobal Anthrax Vaccines Market Analysis and Forecast 2026-2032212 pages · $4,950 USD

Market perspective

Anthrax is a serious disease that can affect both animals and humans. It is caused by bacteria called Bacillus anthracis. People can get anthrax from contact with infected animals, wool, meat, or hides.Anthrax vaccine protects against anthrax disease. Anthrax vaccine was licensed in 1970.Based on limited but sound evidence, the vaccine protects against both cutaneous (skin) and inhalation anthrax.

Global Anthrax Vaccines key players include Emergent BioSolutions, Merial, Merck, Zoetis, PharmAthene, etc. Global top five players hold a share about 70%.

North America is the largest market, with a share about 60%, followed by Latin America and Europe, having a total share about 20 percent.

Read the full market overview

In terms of product, Live Vaccines is the largest segment, with a share about 95%. And in terms of application, the largest application is Human Use, followed by Animal Use.

This report provides an overview of the global Anthrax Vaccines market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Anthrax Vaccines and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Anthrax Vaccines sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Anthrax Vaccines market size, projected growth trends, production technologies, key applications, and end-use industries.

Anthrax Vaccines Segment by Company

Emergent BioSolutions

Merial

Merck

Zoetis

Bayer Sanidad Animal

Colorado Serum

PharmAthene

Tiankang

Biogénesis-Bago

CAVAC

Rosenbusch

Agrovet

Vecol

CVCRI

IVPM

Prondil

CDV

Indian Immunologicals

Botswana Vaccine Institute

Ceva Santé Animale

Intervac

JOVAC

Anthrax Vaccines Segment by Type

Live Vaccines

Cell free PA Vaccines

Anthrax Vaccines Segment by Application

Human Use

Animal Use

Anthrax Vaccines Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Anthrax Vaccines status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Anthrax Vaccines market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Anthrax Vaccines significant trends, drivers, influence factors in global and regions.

6. To analyze Anthrax Vaccines competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Anthrax Vaccines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Anthrax Vaccines and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Anthrax Vaccines.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Anthrax Vaccines market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Anthrax Vaccines industry.

Chapter 3: Detailed analysis of Anthrax Vaccines manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Anthrax Vaccines in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Anthrax Vaccines in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Anthrax Vaccines Industry Trends Table 2. Anthrax Vaccines Industry Drivers Table 3. Anthrax Vaccines Industry Opportunities and Challenges Table 4. Anthrax Vaccines Industry Restraints Table 5. Global Anthrax Vaccines Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Anthrax Vaccines Revenue Share by Company (2021-2026) Table 7. Global Anthrax Vaccines Sales Volume by Company (M Doses) & (2021-2026) Table 8. Global Anthrax Vaccines Sales Volume Share by Company (2021-2026) Table 9. Global Anthrax Vaccines Average Price (USD/Dose) of Company (2021-2026) Table 10. Global Anthrax Vaccines Company Ranking, (2024-2026) & (USD Million) Table 11. Global Anthrax Vaccines Key Company Manufacturing Base & Headquarters Table 12. Global Anthrax Vaccines Company, Product Type & Application Table 13. Global Anthrax Vaccines Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Anthrax Vaccines by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Live Vaccines Table 18. Significant Companies of Cell free PA Vaccines Table 19. Global Anthrax Vaccines Sales Volume by Type 2021 VS 2025 VS 2032 (M Doses) Table 20. Global Anthrax Vaccines Sales Volume by Type (2021-2026) & (M Doses) Table 21. Global Anthrax Vaccines Sales Volume by Type (2027-2032) & (M Doses) Table 22. Global Anthrax Vaccines Sales Volume Share by Type (2021-2026) Table 23. Global Anthrax Vaccines Sales Volume Share by Type (2027-2032) Table 24. Global Anthrax Vaccines Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Anthrax Vaccines Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Anthrax Vaccines Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Anthrax Vaccines Sales Value Share by Type (2021-2026) Table 28. Global Anthrax Vaccines Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Human Use Table 30. Significant Companies of Animal Use Table 31. Global Anthrax Vaccines Sales Volume by Application 2021 VS 2025 VS 2032 (M Doses) Table 32. Global Anthrax Vaccines Sales Volume by Application (2021-2026) & (M Doses) Table 33. Global Anthrax Vaccines Sales Volume by Application (2027-2032) & (M Doses) Table 34. Global Anthrax Vaccines Sales Volume Share by Application (2021-2026) Table 35. Global Anthrax Vaccines Sales Volume Share by Application (2027-2032) Table 36. Global Anthrax Vaccines Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Anthrax Vaccines Sales Value by Application (2021-2026) & (US$ Million) Table 38. Global Anthrax Vaccines Sales Value by Application (2027-2032) & (US$ Million) Table 39. Global Anthrax Vaccines Sales Value Share by Application (2021-2026) Table 40. Global Anthrax Vaccines Sales Value Share by Application (2027-2032) Table 41. Global Anthrax Vaccines Sales by Region: 2021 VS 2025 VS 2032 (M Doses) Table 42. Global Anthrax Vaccines Sales by Region (2021-2026) & (M Doses) Table 43. Global Anthrax Vaccines Sales Market Share by Region (2021-2026) Table 44. Global Anthrax Vaccines Sales by Region (2027-2032) & (M Doses) Table 45. Global Anthrax Vaccines Sales Market Share by Region (2027-2032) Table 46. Global Anthrax Vaccines Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 47. Global Anthrax Vaccines Sales Value by Region (2021-2026) & (US$ Million) Table 48. Global Anthrax Vaccines Sales Value Share by Region (2021-2026) Table 49. Global Anthrax Vaccines Sales Value by Region (2027-2032) & (US$ Million) Table 50. Global Anthrax Vaccines Sales Value Share by Region (2027-2032) Table 51. Global Anthrax Vaccines Market Average Price (USD/Dose) by Region (2021-2026) Table 52. Global Anthrax Vaccines Market Average Price (USD/Dose) by Region (2027-2032) Table 53. Global Anthrax Vaccines Sales by Country: 2021 VS 2025 VS 2032 (M Doses) Table 54. Global Anthrax Vaccines Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 55. Global Anthrax Vaccines Sales by Country (2021-2026) & (M Doses) Table 56. Global Anthrax Vaccines Sales Market Share by Country (2021-2026) Table 57. Global Anthrax Vaccines Sales by Country (2027-2032) & (M Doses) Table 58. Global Anthrax Vaccines Sales Market Share by Country (2027-2032) Table 59. Global Anthrax Vaccines Sales Value by Country (2021-2026) & (US$ Million) Table 60. Global Anthrax Vaccines Sales Value Market Share by Country (2021-2026) Table 61. Global Anthrax Vaccines Sales Value by Country (2027-2032) & (US$ Million) Table 62. Global Anthrax Vaccines Sales Value Market Share by Country (2027-2032) Table 63. Emergent BioSolutions Company Information Table 64. Emergent BioSolutions Business Overview Table 65. Emergent BioSolutions Anthrax Vaccines Sales (M Doses), Value (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 66. Emergent BioSolutions Anthrax Vaccines Product Portfolio Table 67. Emergent BioSolutions Recent Development Table 68. Merial Company Information Table 69. Merial Business Overview Table 70. Merial Anthrax Vaccines Sales (M Doses), Value (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 71. Merial Anthrax Vaccines Product Portfolio Table 72. Merial Recent Development Table 73. Merck Company Information Table 74. Merck Business Overview Table 75. Merck Anthrax Vaccines Sales (M Doses), Value (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 76. Merck Anthrax Vaccines Product Portfolio Table 77. Merck Recent Development Table 78. Zoetis Company Information Table 79. Zoetis Business Overview Table 80. Zoetis Anthrax Vaccines Sales (M Doses), Value (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 81. Zoetis Anthrax Vaccines Product Portfolio Table 82. Zoetis Recent Development Table 83. Bayer Sanidad Animal Company Information Table 84. Bayer Sanidad Animal Business Overview Table 85. Bayer Sanidad Animal Anthrax Vaccines Sales (M Doses), Value (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 86. Bayer Sanidad Animal Anthrax Vaccines Product Portfolio Table 87. Bayer Sanidad Animal Recent Development Table 88. Colorado Serum Company Information Table 89. Colorado Serum Business Overview Table 90. Colorado Serum Anthrax Vaccines Sales (M Doses), Value (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 91. Colorado Serum Anthrax Vaccines Product Portfolio Table 92. Colorado Serum Recent Development Table 93. PharmAthene Company Information Table 94. PharmAthene Business Overview Table 95. PharmAthene Anthrax Vaccines Sales (M Doses), Value (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 96. PharmAthene Anthrax Vaccines Product Portfolio Table 97. PharmAthene Recent Development Table 98. Tiankang Company Information Table 99. Tiankang Business Overview Table 100. Tiankang Anthrax Vaccines Sales (M Doses), Value (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 101. Tiankang Anthrax Vaccines Product Portfolio Table 102. Tiankang Recent Development Table 103. Biogénesis-Bago Company Information Table 104. Biogénesis-Bago Business Overview Table 105. Biogénesis-Bago Anthrax Vaccines Sales (M Doses), Value (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 106. Biogénesis-Bago Anthrax Vaccines Product Portfolio Table 107. Biogénesis-Bago Recent Development Table 108. CAVAC Company Information Table 109. CAVAC Business Overview Table 110. CAVAC Anthrax Vaccines Sales (M Doses), Value (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 111. CAVAC Anthrax Vaccines Product Portfolio Table 112. CAVAC Recent Development Table 113. Rosenbusch Company Information Table 114. Rosenbusch Business Overview Table 115. Rosenbusch Anthrax Vaccines Sales (M Doses), Value (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 116. Rosenbusch Anthrax Vaccines Product Portfolio Table 117. Rosenbusch Recent Development Table 118. Agrovet Company Information Table 119. Agrovet Business Overview Table 120. Agrovet Anthrax Vaccines Sales (M Doses), Value (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 121. Agrovet Anthrax Vaccines Product Portfolio Table 122. Agrovet Recent Development Table 123. Vecol Company Information Table 124. Vecol Business Overview Table 125. Vecol Anthrax Vaccines Sales (M Doses), Value (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 126. Vecol Anthrax Vaccines Product Portfolio Table 127. Vecol Recent Development Table 128. CVCRI Company Information Table 129. CVCRI Business Overview Table 130. CVCRI Anthrax Vaccines Sales (M Doses), Value (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 131. CVCRI Anthrax Vaccines Product Portfolio Table 132. CVCRI Recent Development Table 133. IVPM Company Information Table 134. IVPM Business Overview Table 135. IVPM Anthrax Vaccines Sales (M Doses), Value (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 136. IVPM Anthrax Vaccines Product Portfolio Table 137. IVPM Recent Development Table 138. Prondil Company Information Table 139. Prondil Business Overview Table 140. Prondil Anthrax Vaccines Sales (M Doses), Value (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 141. Prondil Anthrax Vaccines Product Portfolio Table 142. Prondil Recent Development Table 143. CDV Company Information Table 144. CDV Business Overview Table 145. CDV Anthrax Vaccines Sales (M Doses), Value (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 146. CDV Anthrax Vaccines Product Portfolio Table 147. CDV Recent Development Table 148. Indian Immunologicals Company Information Table 149. Indian Immunologicals Business Overview Table 150. Indian Immunologicals Anthrax Vaccines Sales (M Doses), Value (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 151. Indian Immunologicals Anthrax Vaccines Product Portfolio Table 152. Indian Immunologicals Recent Development Table 153. Botswana Vaccine Institute Company Information Table 154. Botswana Vaccine Institute Business Overview Table 155. Botswana Vaccine Institute Anthrax Vaccines Sales (M Doses), Value (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 156. Botswana Vaccine Institute Anthrax Vaccines Product Portfolio Table 157. Botswana Vaccine Institute Recent Development Table 158. Ceva Santé Animale Company Information Table 159. Ceva Santé Animale Business Overview Table 160. Ceva Santé Animale Anthrax Vaccines Sales (M Doses), Value (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 161. Ceva Santé Animale Anthrax Vaccines Product Portfolio Table 162. Ceva Santé Animale Recent Development Table 163. Intervac Company Information Table 164. Intervac Business Overview Table 165. Intervac Anthrax Vaccines Sales (M Doses), Value (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 166. Intervac Anthrax Vaccines Product Portfolio Table 167. Intervac Recent Development Table 168. JOVAC Company Information Table 169. JOVAC Business Overview Table 170. JOVAC Anthrax Vaccines Sales (M Doses), Value (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 171. JOVAC Anthrax Vaccines Product Portfolio Table 172. JOVAC Recent Development Table 173. Key Raw Materials Table 174. Raw Materials Key Suppliers Table 175. Anthrax Vaccines Distributors List Table 176. Anthrax Vaccines Customers List Table 177. Research Programs/Design for This Report Table 178. Authors List of This Report Table 179. Secondary Sources Table 180. Primary Sources List of Figures Figure 1. Anthrax Vaccines Product Image Figure 2. Global Anthrax Vaccines Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Anthrax Vaccines Sales Value (2021-2032) & (US$ Million) Figure 4. Global Anthrax Vaccines Sales (2021-2032) & (M Doses) Figure 5. Global Anthrax Vaccines Sales Average Price (USD/Dose) & (2021-2032) Figure 6. Global Anthrax Vaccines Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Live Vaccines Image Figure 10. Cell free PA Vaccines Image Figure 11. Global Anthrax Vaccines Sales Volume by Type (2021 VS 2025 VS 2032) & (M Doses) Figure 12. Global Anthrax Vaccines Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Anthrax Vaccines Sales Volume Share by Type (2021-2032) Figure 14. Global Anthrax Vaccines Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Anthrax Vaccines Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Anthrax Vaccines Sales Value Share by Type (2021-2032) Figure 17. Human Use Image Figure 18. Animal Use Image Figure 19. Global Anthrax Vaccines Sales Volume by Application (2021 VS 2025 VS 2032) & (M Doses) Figure 20. Global Anthrax Vaccines Sales Volume Share 2021 VS 2025 VS 2032 Figure 21. Global Anthrax Vaccines Sales Volume Share by Application (2021-2032) Figure 22. Global Anthrax Vaccines Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Anthrax Vaccines Sales Value Share 2021 VS 2025 VS 2032 Figure 24. Global Anthrax Vaccines Sales Value Share by Application (2021-2032) Figure 25. Global Anthrax Vaccines Sales by Region: 2021 VS 2025 VS 2032 (M Doses) Figure 26. Global Anthrax Vaccines Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 27. Global Anthrax Vaccines Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 28. Global Anthrax Vaccines Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 29. North America Anthrax Vaccines Sales Value (2021-2032) & (US$ Million) Figure 30. North America Anthrax Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Europe Anthrax Vaccines Sales Value (2021-2032) & (US$ Million) Figure 32. Europe Anthrax Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Asia-Pacific Anthrax Vaccines Sales Value (2021-2032) & (US$ Million) Figure 34. Asia-Pacific Anthrax Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 35. South America Anthrax Vaccines Sales Value (2021-2032) & (US$ Million) Figure 36. South America Anthrax Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Middle East & Africa Anthrax Vaccines Sales Value (2021-2032) & (US$ Million) Figure 38. Middle East & Africa Anthrax Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 39. USA Anthrax Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. USA Anthrax Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. USA Anthrax Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Canada Anthrax Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Canada Anthrax Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Canada Anthrax Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Mexico Anthrax Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Mexico Anthrax Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Mexico Anthrax Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Germany Anthrax Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Germany Anthrax Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Germany Anthrax Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. France Anthrax Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. France Anthrax Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. France Anthrax Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. U.K. Anthrax Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. U.K. Anthrax Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. U.K. Anthrax Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Italy Anthrax Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Italy Anthrax Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Italy Anthrax Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Spain Anthrax Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Spain Anthrax Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Spain Anthrax Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Russia Anthrax Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Russia Anthrax Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Russia Anthrax Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Netherlands Anthrax Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Netherlands Anthrax Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Netherlands Anthrax Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Nordic Countries Anthrax Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Nordic Countries Anthrax Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Nordic Countries Anthrax Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. China Anthrax Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. China Anthrax Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. China Anthrax Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Japan Anthrax Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Japan Anthrax Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Japan Anthrax Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. South Korea Anthrax Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. South Korea Anthrax Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. South Korea Anthrax Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. India Anthrax Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. India Anthrax Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. India Anthrax Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Australia Anthrax Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Australia Anthrax Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Australia Anthrax Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Southeast Asia Anthrax Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Southeast Asia Anthrax Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Southeast Asia Anthrax Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Brazil Anthrax Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Brazil Anthrax Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Brazil Anthrax Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Argentina Anthrax Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Argentina Anthrax Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Argentina Anthrax Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Chile Anthrax Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Chile Anthrax Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Chile Anthrax Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Colombia Anthrax Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Colombia Anthrax Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Colombia Anthrax Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Peru Anthrax Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Peru Anthrax Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Peru Anthrax Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Saudi Arabia Anthrax Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Saudi Arabia Anthrax Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Anthrax Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Israel Anthrax Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Israel Arabia Anthrax Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Israel Arabia Anthrax Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. UAE Anthrax Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. UAE Anthrax Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. UAE Anthrax Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Turkey Anthrax Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Turkey Anthrax Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Turkey Anthrax Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Iran Anthrax Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Iran Anthrax Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Iran Anthrax Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Egypt Anthrax Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Egypt Anthrax Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Egypt Anthrax Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Anthrax Vaccines Value Chain Figure 124. Manufacturing Cost Structure Figure 125. Anthrax Vaccines Sales Mode & Process Figure 126. Direct Comparison with Distribution Share Figure 127. Distributors Profiles Figure 128. Years Considered Figure 129. Research Process Figure 130. Key Executives Interviewed

Scope & coverage.

Types
  • Live Vaccines
  • Cell free PA Vaccines
Applications
  • Human Use
  • Animal Use
Companies covered
  • Emergent BioSolutions
  • Merial
  • Merck
  • Zoetis
  • Bayer Sanidad Animal
  • Colorado Serum
  • PharmAthene
  • Tiankang
  • Biogénesis-Bago
  • CAVAC
  • Rosenbusch
  • Agrovet
  • Vecol
  • CVCRI
  • IVPM
  • Prondil
  • CDV
  • Indian Immunologicals
  • Botswana Vaccine Institute
  • Ceva Santé Animale
  • Intervac
  • JOVAC

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Anthrax Vaccines Sales Value (2021-2032)
  4. 1.2.2 Global Anthrax Vaccines Sales Volume (2021-2032)
  5. 1.2.3 Global Anthrax Vaccines Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Anthrax Vaccines Market Dynamics
  1. 2.1 Anthrax Vaccines Industry Trends
  2. 2.2 Anthrax Vaccines Industry Drivers
  3. 2.3 Anthrax Vaccines Industry Opportunities and Challenges
  4. 2.4 Anthrax Vaccines Industry Restraints
3 Anthrax Vaccines Market by Company
  1. 3.1 Global Anthrax Vaccines Company Revenue Ranking in 2025
  2. 3.2 Global Anthrax Vaccines Revenue by Company (2021-2026)
  3. 3.3 Global Anthrax Vaccines Sales Volume by Company (2021-2026)
  4. 3.4 Global Anthrax Vaccines Average Price by Company (2021-2026)
  5. 3.5 Global Anthrax Vaccines Company Ranking (2024-2026)
  6. 3.6 Global Anthrax Vaccines Company Manufacturing Base and Headquarters
  7. 3.7 Global Anthrax Vaccines Company Product Type and Application
  8. 3.8 Global Anthrax Vaccines Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Anthrax Vaccines Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Anthrax Vaccines Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Anthrax Vaccines Market by Type
  1. 4.1 Anthrax Vaccines Type Introduction
  2. 4.1.1 Live Vaccines
  3. 4.1.2 Cell free PA Vaccines
  4. 4.2 Global Anthrax Vaccines Sales Volume by Type
  5. 4.2.1 Global Anthrax Vaccines Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Anthrax Vaccines Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Anthrax Vaccines Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Anthrax Vaccines Sales Value by Type
  9. 4.3.1 Global Anthrax Vaccines Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Anthrax Vaccines Sales Value by Type (2021-2032)
  11. 4.3.3 Global Anthrax Vaccines Sales Value Share by Type (2021-2032)
5 Anthrax Vaccines Market by Application
  1. 5.1 Anthrax Vaccines Application Introduction
  2. 5.1.1 Human Use
  3. 5.1.2 Animal Use
  4. 5.2 Global Anthrax Vaccines Sales Volume by Application
  5. 5.2.1 Global Anthrax Vaccines Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Anthrax Vaccines Sales Volume by Application (2021-2032)
  7. 5.2.3 Global Anthrax Vaccines Sales Volume Share by Application (2021-2032)
  8. 5.3 Global Anthrax Vaccines Sales Value by Application
  9. 5.3.1 Global Anthrax Vaccines Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Anthrax Vaccines Sales Value by Application (2021-2032)
  11. 5.3.3 Global Anthrax Vaccines Sales Value Share by Application (2021-2032)
6 Anthrax Vaccines Regional Sales and Value Analysis
  1. 6.1 Global Anthrax Vaccines Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Anthrax Vaccines Sales by Region (2021-2032)
  3. 6.2.1 Global Anthrax Vaccines Sales by Region: 2021-2026
  4. 6.2.2 Global Anthrax Vaccines Sales by Region (2027-2032)
  5. 6.3 Global Anthrax Vaccines Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Anthrax Vaccines Sales Value by Region (2021-2032)
  7. 6.4.1 Global Anthrax Vaccines Sales Value by Region: 2021-2026
  8. 6.4.2 Global Anthrax Vaccines Sales Value by Region (2027-2032)
  9. 6.5 Global Anthrax Vaccines Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Anthrax Vaccines Sales Value (2021-2032)
  12. 6.6.2 North America Anthrax Vaccines Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Anthrax Vaccines Sales Value (2021-2032)
  15. 6.7.2 Europe Anthrax Vaccines Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Anthrax Vaccines Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Anthrax Vaccines Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Anthrax Vaccines Sales Value (2021-2032)
  21. 6.9.2 South America Anthrax Vaccines Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Anthrax Vaccines Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Anthrax Vaccines Sales Value Share by Country, 2025 VS 2032
7 Anthrax Vaccines Country-level Sales and Value Analysis
  1. 7.1 Global Anthrax Vaccines Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Anthrax Vaccines Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Anthrax Vaccines Sales by Country (2021-2032)
  4. 7.3.1 Global Anthrax Vaccines Sales by Country (2021-2026)
  5. 7.3.2 Global Anthrax Vaccines Sales by Country (2027-2032)
  6. 7.4 Global Anthrax Vaccines Sales Value by Country (2021-2032)
  7. 7.4.1 Global Anthrax Vaccines Sales Value by Country (2021-2026)
  8. 7.4.2 Global Anthrax Vaccines Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Anthrax Vaccines Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Anthrax Vaccines Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Anthrax Vaccines Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Anthrax Vaccines Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Anthrax Vaccines Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Anthrax Vaccines Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Anthrax Vaccines Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Anthrax Vaccines Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Anthrax Vaccines Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Anthrax Vaccines Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Anthrax Vaccines Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Anthrax Vaccines Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Anthrax Vaccines Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Anthrax Vaccines Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Anthrax Vaccines Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Anthrax Vaccines Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Anthrax Vaccines Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Anthrax Vaccines Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Anthrax Vaccines Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Anthrax Vaccines Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Anthrax Vaccines Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Anthrax Vaccines Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Anthrax Vaccines Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Anthrax Vaccines Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Anthrax Vaccines Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Anthrax Vaccines Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Anthrax Vaccines Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Anthrax Vaccines Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Anthrax Vaccines Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Anthrax Vaccines Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Anthrax Vaccines Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Anthrax Vaccines Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Anthrax Vaccines Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Anthrax Vaccines Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Anthrax Vaccines Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Anthrax Vaccines Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Anthrax Vaccines Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Anthrax Vaccines Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Anthrax Vaccines Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Anthrax Vaccines Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Anthrax Vaccines Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Anthrax Vaccines Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Anthrax Vaccines Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Anthrax Vaccines Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Anthrax Vaccines Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Anthrax Vaccines Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Anthrax Vaccines Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Anthrax Vaccines Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Anthrax Vaccines Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Anthrax Vaccines Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Anthrax Vaccines Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Anthrax Vaccines Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Anthrax Vaccines Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Anthrax Vaccines Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Anthrax Vaccines Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Anthrax Vaccines Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Anthrax Vaccines Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Anthrax Vaccines Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Anthrax Vaccines Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Anthrax Vaccines Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Anthrax Vaccines Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Anthrax Vaccines Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Anthrax Vaccines Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Anthrax Vaccines Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Anthrax Vaccines Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Anthrax Vaccines Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Anthrax Vaccines Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Anthrax Vaccines Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Anthrax Vaccines Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Anthrax Vaccines Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Anthrax Vaccines Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Anthrax Vaccines Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Anthrax Vaccines Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Anthrax Vaccines Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Anthrax Vaccines Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Anthrax Vaccines Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Anthrax Vaccines Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Anthrax Vaccines Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Anthrax Vaccines Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Anthrax Vaccines Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Anthrax Vaccines Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Anthrax Vaccines Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Anthrax Vaccines Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Anthrax Vaccines Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Emergent BioSolutions
  2. 8.1.1 Emergent BioSolutions Company Information
  3. 8.1.2 Emergent BioSolutions Business Overview
  4. 8.1.3 Emergent BioSolutions Anthrax Vaccines Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Emergent BioSolutions Anthrax Vaccines Product Portfolio
  6. 8.1.5 Emergent BioSolutions Recent Developments
  7. 8.2 Merial
  8. 8.2.1 Merial Company Information
  9. 8.2.2 Merial Business Overview
  10. 8.2.3 Merial Anthrax Vaccines Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Merial Anthrax Vaccines Product Portfolio
  12. 8.2.5 Merial Recent Developments
  13. 8.3 Merck
  14. 8.3.1 Merck Company Information
  15. 8.3.2 Merck Business Overview
  16. 8.3.3 Merck Anthrax Vaccines Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Merck Anthrax Vaccines Product Portfolio
  18. 8.3.5 Merck Recent Developments
  19. 8.4 Zoetis
  20. 8.4.1 Zoetis Company Information
  21. 8.4.2 Zoetis Business Overview
  22. 8.4.3 Zoetis Anthrax Vaccines Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Zoetis Anthrax Vaccines Product Portfolio
  24. 8.4.5 Zoetis Recent Developments
  25. 8.5 Bayer Sanidad Animal
  26. 8.5.1 Bayer Sanidad Animal Company Information
  27. 8.5.2 Bayer Sanidad Animal Business Overview
  28. 8.5.3 Bayer Sanidad Animal Anthrax Vaccines Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Bayer Sanidad Animal Anthrax Vaccines Product Portfolio
  30. 8.5.5 Bayer Sanidad Animal Recent Developments
  31. 8.6 Colorado Serum
  32. 8.6.1 Colorado Serum Company Information
  33. 8.6.2 Colorado Serum Business Overview
  34. 8.6.3 Colorado Serum Anthrax Vaccines Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Colorado Serum Anthrax Vaccines Product Portfolio
  36. 8.6.5 Colorado Serum Recent Developments
  37. 8.7 PharmAthene
  38. 8.7.1 PharmAthene Company Information
  39. 8.7.2 PharmAthene Business Overview
  40. 8.7.3 PharmAthene Anthrax Vaccines Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 PharmAthene Anthrax Vaccines Product Portfolio
  42. 8.7.5 PharmAthene Recent Developments
  43. 8.8 Tiankang
  44. 8.8.1 Tiankang Company Information
  45. 8.8.2 Tiankang Business Overview
  46. 8.8.3 Tiankang Anthrax Vaccines Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Tiankang Anthrax Vaccines Product Portfolio
  48. 8.8.5 Tiankang Recent Developments
  49. 8.9 Biogénesis-Bago
  50. 8.9.1 Biogénesis-Bago Company Information
  51. 8.9.2 Biogénesis-Bago Business Overview
  52. 8.9.3 Biogénesis-Bago Anthrax Vaccines Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Biogénesis-Bago Anthrax Vaccines Product Portfolio
  54. 8.9.5 Biogénesis-Bago Recent Developments
  55. 8.10 CAVAC
  56. 8.10.1 CAVAC Company Information
  57. 8.10.2 CAVAC Business Overview
  58. 8.10.3 CAVAC Anthrax Vaccines Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 CAVAC Anthrax Vaccines Product Portfolio
  60. 8.10.5 CAVAC Recent Developments
  61. 8.11 Rosenbusch
  62. 8.11.1 Rosenbusch Company Information
  63. 8.11.2 Rosenbusch Business Overview
  64. 8.11.3 Rosenbusch Anthrax Vaccines Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Rosenbusch Anthrax Vaccines Product Portfolio
  66. 8.11.5 Rosenbusch Recent Developments
  67. 8.12 Agrovet
  68. 8.12.1 Agrovet Company Information
  69. 8.12.2 Agrovet Business Overview
  70. 8.12.3 Agrovet Anthrax Vaccines Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Agrovet Anthrax Vaccines Product Portfolio
  72. 8.12.5 Agrovet Recent Developments
  73. 8.13 Vecol
  74. 8.13.1 Vecol Company Information
  75. 8.13.2 Vecol Business Overview
  76. 8.13.3 Vecol Anthrax Vaccines Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Vecol Anthrax Vaccines Product Portfolio
  78. 8.13.5 Vecol Recent Developments
  79. 8.14 CVCRI
  80. 8.14.1 CVCRI Company Information
  81. 8.14.2 CVCRI Business Overview
  82. 8.14.3 CVCRI Anthrax Vaccines Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 CVCRI Anthrax Vaccines Product Portfolio
  84. 8.14.5 CVCRI Recent Developments
  85. 8.15 IVPM
  86. 8.15.1 IVPM Company Information
  87. 8.15.2 IVPM Business Overview
  88. 8.15.3 IVPM Anthrax Vaccines Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 IVPM Anthrax Vaccines Product Portfolio
  90. 8.15.5 IVPM Recent Developments
  91. 8.16 Prondil
  92. 8.16.1 Prondil Company Information
  93. 8.16.2 Prondil Business Overview
  94. 8.16.3 Prondil Anthrax Vaccines Sales, Value and Gross Margin (2021-2026)
  95. 8.16.4 Prondil Anthrax Vaccines Product Portfolio
  96. 8.16.5 Prondil Recent Developments
  97. 8.17 CDV
  98. 8.17.1 CDV Company Information
  99. 8.17.2 CDV Business Overview
  100. 8.17.3 CDV Anthrax Vaccines Sales, Value and Gross Margin (2021-2026)
  101. 8.17.4 CDV Anthrax Vaccines Product Portfolio
  102. 8.17.5 CDV Recent Developments
  103. 8.18 Indian Immunologicals
  104. 8.18.1 Indian Immunologicals Company Information
  105. 8.18.2 Indian Immunologicals Business Overview
  106. 8.18.3 Indian Immunologicals Anthrax Vaccines Sales, Value and Gross Margin (2021-2026)
  107. 8.18.4 Indian Immunologicals Anthrax Vaccines Product Portfolio
  108. 8.18.5 Indian Immunologicals Recent Developments
  109. 8.19 Botswana Vaccine Institute
  110. 8.19.1 Botswana Vaccine Institute Company Information
  111. 8.19.2 Botswana Vaccine Institute Business Overview
  112. 8.19.3 Botswana Vaccine Institute Anthrax Vaccines Sales, Value and Gross Margin (2021-2026)
  113. 8.19.4 Botswana Vaccine Institute Anthrax Vaccines Product Portfolio
  114. 8.19.5 Botswana Vaccine Institute Recent Developments
  115. 8.20 Ceva Santé Animale
  116. 8.20.1 Ceva Santé Animale Company Information
  117. 8.20.2 Ceva Santé Animale Business Overview
  118. 8.20.3 Ceva Santé Animale Anthrax Vaccines Sales, Value and Gross Margin (2021-2026)
  119. 8.20.4 Ceva Santé Animale Anthrax Vaccines Product Portfolio
  120. 8.20.5 Ceva Santé Animale Recent Developments
  121. 8.21 Intervac
  122. 8.21.1 Intervac Company Information
  123. 8.21.2 Intervac Business Overview
  124. 8.21.3 Intervac Anthrax Vaccines Sales, Value and Gross Margin (2021-2026)
  125. 8.21.4 Intervac Anthrax Vaccines Product Portfolio
  126. 8.21.5 Intervac Recent Developments
  127. 8.22 JOVAC
  128. 8.22.1 JOVAC Company Information
  129. 8.22.2 JOVAC Business Overview
  130. 8.22.3 JOVAC Anthrax Vaccines Sales, Value and Gross Margin (2021-2026)
  131. 8.22.4 JOVAC Anthrax Vaccines Product Portfolio
  132. 8.22.5 JOVAC Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Anthrax Vaccines Value Chain Analysis
  2. 9.1.1 Anthrax Vaccines Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Anthrax Vaccines Sales Mode & Process
  6. 9.2 Anthrax Vaccines Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Anthrax Vaccines Distributors
  9. 9.2.3 Anthrax Vaccines Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst